blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4183787

EP4183787 - MORPHINAN COMPOUNDS [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  10.06.2024
Database last updated on 02.07.2024
FormerRequest for examination was made
Status updated on  21.04.2023
Most recent event   Tooltip10.06.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Sun Pharmaceutical Industries, Inc.
2 Independence Way
Princeton, NJ 08540 / US
[2023/31]
Former [2023/21]For all designated states
Concert Pharmaceuticals Inc.
99 Hayden Avenue, Suite 500
Lexington, MA 02421 / US
Inventor(s)01 / TUNG, Roger
Lexington, 02420 / US
 [2023/21]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[2023/21]
Application number, filing date22199041.930.04.2008
[2023/21]
Priority number, dateUS200791513007P01.05.2007         Original published format: US 91513007 P
US200791666207P08.05.2007         Original published format: US 91666207 P
US200797604407P28.09.2007         Original published format: US 97604407 P
[2023/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4183787
Date:24.05.2023
Language:EN
[2023/21]
Search report(s)(Supplementary) European search report - dispatched on:EP21.04.2023
ClassificationIPC:C07D471/08, C07B59/00, A61K31/439, A61P11/14
[2023/21]
CPC:
A61K31/195 (EP,US); C12Q1/28 (US); A61K31/4709 (EP,US);
A61K31/485 (EP,US); A61K31/49 (EP,US); A61P11/00 (EP);
A61P11/14 (EP); A61P25/00 (EP); C07B59/002 (EP,US);
C07D221/28 (EP,US); C07D471/08 (EP,US); G01N33/491 (EP,US);
G01N33/493 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2023/21]
TitleGerman:MORPHINANVERBINDUNGEN[2023/21]
English:MORPHINAN COMPOUNDS[2023/21]
French:COMPOSÉS DE MORPHINANE[2023/21]
Examination procedure30.09.2022Examination requested  [2023/21]
13.11.2023Amendment by applicant (claims and/or description)
13.11.2023Date on which the examining division has become responsible
11.06.2024Communication of intention to grant the patent
Parent application(s)   TooltipEP08747238.7  / EP2152709
EP11000764.8  / EP2357183
EP14173190.1  / EP2792662
EP16163718.6  / EP3093290
EP17206213.5  / EP3357923
EP19201663.2  / EP3632916
EP20200633.4  / EP3825306
Fees paidRenewal fee
30.09.2022Renewal fee patent year 03
30.09.2022Renewal fee patent year 04
30.09.2022Renewal fee patent year 05
30.09.2022Renewal fee patent year 06
30.09.2022Renewal fee patent year 07
30.09.2022Renewal fee patent year 08
30.09.2022Renewal fee patent year 09
30.09.2022Renewal fee patent year 10
30.09.2022Renewal fee patent year 11
30.09.2022Renewal fee patent year 12
30.09.2022Renewal fee patent year 13
30.09.2022Renewal fee patent year 14
30.09.2022Renewal fee patent year 15
27.04.2023Renewal fee patent year 16
22.03.2024Renewal fee patent year 17
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO0141707  (UNIV VANDERBILT [US]) [A] 1-8* example 1; claim - *;
 [A]  - G. HEINKELE ET. AL., "Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-beta-glucoronide", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, (2002), vol. 45, pages 1153 - 1158, XP002490642 [A] 1-8 * whole article *

DOI:   http://dx.doi.org/10.1002/jlcr.640
 [A]  - T.H. EICHHOLD ET. AL., "Highly sensitive high-peformance liquid chromatographic-tandem mass spectrometric method for the analysis of dextromorphan in human plasma.", JOURNAL OF CHROMATOGRAPHY B, (1997), vol. 698, pages 147 - 154, XP002490644 [A] 1-8 * figure 1 *

DOI:   http://dx.doi.org/10.1016/S0378-4347(97)00308-3
 [A]  - G. HEINKELE ET. AL., "Synthesis of [2H]-labelled phase I metabolites using 1-[2H]-pyridinium hydrochloride.", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, (2005), vol. 48, pages 457 - 461, XP002490645 [A] 1-8 * figure 1 *

DOI:   http://dx.doi.org/10.1002/jlcr.941
 [AP]  - H. BÖLCSKEI ET. AL., "Synthesis of deuterated dextromethorphan derivatives.", ARKIVOK, (20080301), vol. 2008, no. iii, pages 182 - 193, XP002490643 [AP] 1-8 * page 183 - page 184; figure 1 *
by applicantUS4316888
 US4446140
 US4694010
 US4898860
 US5166207
 US5304121
 US5336980
 US5350756
 US5366980
 US5863927
 US5886026
 US6099562
 US6197830
 US6207164
 US2001044446
 US2002103109
 USRE38115E
 US6583152
 US2004087479
 US6803031
 US2005129783
 US2005203125
 US7014866
 US2006079502
 US2006094744
 US7114547
 US2007191411
    - MILLER, SC et al., Addict Biol, (20050000), vol. 10, no. 4, pages 325 - 7
    - NICHOLSON, KL et al., Psychopharmacology (Berl, (19990901), vol. 146, no. 1, pages 49 - 59
    - PENDER, ES et al., Pediatr Emerg Care, (19910000), vol. 7, pages 163 - 7
    - ZAWERTAILO LA et al., J Clin Psychopharmacol, (19980800), vol. 18, no. 4, pages 332 - 7
    - GANES LZ et al., Comp Biochem Physiol A Mol Integr Physiol, (19980000), vol. 119, page 725
    - KIM HC et al., Bioorg Med Chem Lett, (20010000), vol. 11, page 1651
    - NEWMAN AH et al., J Med Chem, (19920000), vol. 35, page 4135
    - GANAPATHY MEPRASAD PDHUANG WSETH PLEIBACH FHGANAPATHY V, "Molecular and ligand-binding characterization of the s-receptor in the Jurkat human T lymphocyte cell line", J Pharmacol Exp Ther., (19990000), vol. 289, pages 251 - 260
    - GOLDMAN MEJACOBSON AERICE KCPAUL SM, "Differentiation of [.H] phencyclidine and (+)-[.H]SKF-10047 binding sites in rat cerebral cortex", FEBS Lett., (19850000), vol. 190, doi:10.1016/0014-5793(85)81313-2, pages 333 - 336, XP025604812

DOI:   http://dx.doi.org/10.1016/0014-5793(85)81313-2
    - FREIREICH et al., Cancer Chemother. Rep, (19660000), vol. 50, page 219
    - Scientific Tables, Geigy Pharmaceuticals, (19700000), page 537
    - SIEGEL BWSREEKRISHNA KBARON BM, "Binding of the radiolabeled glycine site antagonist [3H]MDS105,519 to homomeric NMDA-NRla receptors.", Eur J Pharmacol., (19960000), vol. 312, no. 3, pages 357 - 365
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.